ViraVector (VV) is a research infrastructure for the purpose of producing and providing on-demand quality viral vectors to the national research community and other stakeholders. VV is a single-site research infrastructure offering viral vector production and gene transfer in vitro/in vivo experimentation services that features biosafety level 2+ (BSL2) laboratories, where it produces research-grade batches of viral particles (AAV, LV). It also assists investigators in engineering custom viral vectors as well as providing training to safely manipulate them and perform gene transfer in cell and animal models. VV is included in the National Roadmap for Research Infrastructures of Strategic Interest (RNIE) and integrates the PT-cluster of the European Advanced Translational Research Infrastructure in Medicine (EATRIS ERIC) - platforms ATMP & Biological, Biomarkers.

We use cookies to improve your visit to our website.